论文部分内容阅读
目的 分析比较检测尿核基质蛋白 2 2 (NMP 2 2 )、流式细胞术 (FCM)、尿脱落细胞学检查 3种无创方法诊断膀胱移行细胞癌 (BTCC)的临床价值。 方法 将 85例同期住院病人分成BTCC组、泌尿系良性疾病组、泌尿系非尿路上皮恶性肿瘤组 ,分别应用酶联免疫吸附试验 (ELISA)、FCM测定各组病人自排尿中NMP 2 2和DNA含量 ,并同时行尿脱落细胞学检查。 结果 BTCC组、泌尿系良性疾病组、泌尿系非尿路上皮恶性肿瘤组尿NMP 2 2含量的中位数分别为 16 .1U/ml、7.2U/ml、4.5U/ml。BTCC组尿NMP 2 2的含量与其他两组含量差别具有显著性意义 (P <0 .0 5 )。NMP 2 2、FCM、尿脱落细胞诊断BTCC的敏感性分别为 6 1.1%、6 9.4%、18.3%,特异性分别为6 7.4%、5 9.2 %、10 0 %。 结论 尿NMP 2 2测定 ,FCMDNA分析术检测BTCC具有比脱落细胞学更高的敏感性 ,可作为BTCC的辅助诊断手段。
Objective To compare and analyze the clinical value of three kinds of noninvasive methods in detecting bladder transitional cell carcinoma (BTCC), such as NMP 2 2, flow cytometry (FCM) and exfoliative cytology. Methods Eighty-five inpatients in the same period were divided into BTCC group, benign urological group and urinary non-urothelial cancer group. Enzyme-linked immunosorbent assay (ELISA) and FCM were used to detect the NMP 2 2 and DNA content, and at the same time urinary cytology. Results The median urinary NMP 2 2 levels in BTCC group, urological benign disease group and urinary non-urothelial cancer group were 16.1 U / ml, 7.2 U / ml and 4.5 U / ml, respectively. Urinary NMP 2 2 levels in BTCC group were significantly different from other two groups (P <0.05). The sensitivities of NMP 2 2, FCM and urine exfoliated cells in the diagnosis of BTCC were 6 1.1%, 6 9.4% and 18.3%, respectively, and their specificity were 6 7.4%, 52.2% and 100% respectively. Conclusions Urinary NMP 2 2 assay and FCMDNA assay have higher sensitivity than exfoliated cytology and can be used as auxiliary diagnostic tools for BTCC.